



LARGE INCREASE IN REVENUE:

OVER 42% ON THE FINANCIAL YEAR ENDING JUNE 30th, 2014

September 1st, 2014 Montpellier, France – MEDTECH (Euronext, FR0010892950 – ROSA), a company specializing in the design, development and marketing of surgical robots has announced its turnover for the 4th quarter of the financial year ending June 30th, 2014.

<i>In thousands of Euros</i>	2013	2014
9-month revenue	1 477	1 356
4 th quarter revenue	303	1 168
Annual revenue ending June 30th	1 780	2 524

Acceleration in growth for the 4th quarter

In accordance with its development strategy, Medtech's growth accelerated over the last quarter (April-June) with the sale of 5 new ROSA™ Brain robots including 3 in the United States (Emory University School of Medicine, Atlanta, GA – The Cleveland Clinic, Cleveland, OH – Akron General Medical Center, Akron, OH). The dynamics of this activity are a reflection of the first fruits of our strategy to increase the international sales force, especially in the North American territory.

A strong progression in the annual revenue with a 42% increase (financial year ending June 30th, 2014)

With sales going up to 2.5 M€ for the period ending on June 30th 2014, Medtech recorded an increase of 42% compared with the previous period.

On June 30th, 2014, with a fleet of 28 ROSA™ Brain robots delivered worldwide (including 9 during the last financial exercise), Medtech has pursued its strategy of commercial development and the conquest of its markets.

Obtaining the CE marking for ROSA™ Spine

On July 16th, Medtech announced that it had obtained the CE marking for its new ROSA™ Spine robot, designed for minimally invasive spine surgery. From now on, with this official authorization, the ROSA™ Spine robot can be marketed in Europe. The ROSA™ Spine robot's prime application will



Communiqué de Presse



be pedicle screw surgery. There are over one million procedures of this kind performed worldwide every year.

Bertin Nahum, President and Founder of Medtech declared: *«We are very proud of this large step forward which is part of the company's development strategy. The progression in our turnover and obtaining the CE marking for ROSA™ Spine is a reflection of our ability to honor the commitments we made at the time of our IPO. This reinforces Medtech's position as a European leader in surgical robotics ».*

Medtech shares are eligible for the PEA PME SME equity savings plan.

About MEDTECH

MEDTECH, founded in 2002 by Bertin NAHUM and based near Montpellier, is the European specialist in design, development and marketing of innovative robotic-assistive devices for medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less invasive treatment.

In 2006, MEDTECH sold the patent portfolio for its first robot, BRIGIT™, designed for knee surgery, to Zimmer Inc. (NYSE : ZMH).

In 2007, MEDTECH developed ROSA™ Brain, a state-of-the-art robotic device devoted to brain surgery, which has now been officially approved in Europe, the United States and Canada.

With the launching of its latest robot, ROSA™ Spine, MEDTECH has broadened its field of intervention with this new equipment for spinal surgery.

In 2013, MEDTECH received the «European Company of the Year » award in the “robotics neurosurgery » category from Frost & Sullivan.

CONTACT MEDTECH

Christophe Sibillin
Administration and Financial Manager
Tél : +33 (0)4 67 10 77 40

CONTACT for INVESTORS

Corinne Puissant
Tel : +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS CONTACT

Alexandra Prisa
Tel. : +33(0)1 53 67 35 79
aprisa@actus.fr